Quick Answer
Maze Therapeutics, Inc. reported Earnings Per Share Diluted of $3.05 (loss) per share for the year ending 2025.
- Maze Therapeutics, Inc. showed a decrease of -344.0% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Maze Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $13.91 (loss) per share | Q2 2024: $3.22 per share | Q3 2024: $10.25 (loss) per share | Q1 2025: $1.15 (loss) per share | Q2 2025: $0.77 (loss) per share | Q3 2025: $0.66 (loss) per share.
- Historical annual values: Fiscal year 2025: $3.05 (loss) per share | Fiscal year 2024: $1.25 per share.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: